Skip to content

Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer

Standard Silicone-based Breast Implant vs. B-Lite® Light Weight Breast Implant for Reconstructive Surgery After Total Mastectomy and Post-Mastectomy Radiotherapy for Breast Cancer: a Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03737500
Acronym
BLITE-01
Enrollment
49
Registered
2018-11-09
Start date
2018-06-01
Completion date
2021-06-30
Last updated
2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Implant; Complications, Breast Implant Protrusion, Radiotherapy Side Effect

Brief summary

Reconstructive surgery with breast implants after total mastectomy for breast cancer is invariably related to several possible complications, such as atrophy of surrounding tissues, skin thinning, capsular contracture, wound dehiscence and inframammary fold break. Such complications are promoted by elastic properties of tissues and their response to gravity forces exerted on breast implant weight, leading to microischaemic events. A poor cosmetic outcome may result up to breast implant exposure, and its removal may become necessary, thus compromising the quality of breast reconstruction. These complications are further favoured by post-mastectomy radiotherapy (PMRT), since irradiation could enhance microischaemia of peri-prosthetic soft tissues and muscle, with subsequent inadequate healing, fibrosis and thinning. Since PMRT has been associated to improved loco-regional control in node-positive breast cancer patients, its use has increased in recent years. On one hand, PMRT has improved loco-regional control but, on the other hand, it has increased the failure rate of breast reconstruction after total mastectomy. Change of timing in breast reconstruction (immediate vs. two-staged by use of tissue expander) has not decreased the complications rate after PMRT. Currently the failure rate of breast reconstruction after total mastectomy and PMRT ranges from 0% to 40%. The present study will recruit 80 participants affected by breast cancer candidated to total mastectomy with immediate breast reconstruction and subsequent PMRT or total mastectomy with reconstruction by tissue expander, subsequent PMRT and then definitive reconstruction with breast implant. Participants will be randomized in two experimental arms: 40 patients will receive final reconstruction by the use of standard silicone-based breast implant and the other 40 patients will receive B-Lite® light weight breast implant. Participants will be followed up at 1, 6, 12 and 24 months, and all patients will undergo breast MRI at 6 months. The primary goal of the present study is to evaluate the failure rate of breast reconstruction (i.e. the need of re-intervention for breast implant removal). Secondary end-points include the overall complications rate, MRI evaluation of breast implant and surrounding tissues, cosmetic outcomes and quality of life including participants' satisfaction with breast reconstruction.

Interventions

DEVICEB-Lite® light weight breast implant

Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant

DEVICEStandard silicone-based breast implant

Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution

Sponsors

Istituti Clinici Scientifici Maugeri SpA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Breast cancer diagnosis with indication of total mastectomy and breast reconstruction * Indication of post-mastectomy radiation therapy * Availability to be followed up for 24 months * Signature of informed consent

Exclusion criteria

* Patients candidated to breast-conserving surgery * Contraindicated breast reconstruction (severe comorbidities, unfavourable survival outcome expected, distant metastases) * Patients affected by other solid malignancies * Pregnancy * Participation to other clinical studies in the last three months

Design outcomes

Primary

MeasureTime frameDescription
Failure rate of breast reconstruction24 monthsNeed of re-intervention for breast implant removal for any cause (such as breast implant exposure)

Secondary

MeasureTime frameDescription
Overall complications rate24 monthsOccurrence of any complication at any time point, such as: capsular contracture, wound dehiscence, skin/soft tissues necrosis, inframammary fold break, implant exposure treated conservatively, hematoma, peri-prosthetic fluid collection, wound/implant infection
Magnetic resonance imaging (MRI) of breast implant and surrounding tissues6 monthsMRI evaluation for skin/soft tissues thinning, capsular contracture, implant break, chronic seroma
Change in cosmetic outcome1, 6, 12, 24 monthsObjective evaluation of cosmetic outcome by jugular-nipple/areola complex (NAC) and NAC-inframammary fold distances to evaluate symmetry, objective evaluation of plastic surgeon with serial photographs
Change in Quality of life (QoL) measured with BIBCQ6, 12, 24 monthsQoL evaluation included patient's satisfaction with breast reconstruction using the Body Image after Breast Cancer Questionnaire (BIBCQ)
Change in Quality of life (QoL) measured with BREAST-Q6, 12, 24 monthsQoL evaluation included patient's satisfaction with breast reconstruction, using the BREAST-Q score

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026